XBiotech (XBIT)

Executive Summary

XBiotech is a clinical-stage biotechnology company leveraging its proprietary True Human™ antibody platform to develop novel therapeutics for inflammatory diseases, oncology, and infectious diseases. By sourcing antibodies from individuals with natural immunity, the company aims to create safer and more effective treatments. Its lead product, Natrunix (anti-IL-1 alpha), is in Phase 2 clinical trials for rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA), with multiple studies ongoing. XBiotech also has a Phase 1/2 trial for XB2001 in pancreatic cancer. The company’s fully integrated model, including in-house manufacturing, provides operational control and potential cost advantages. Recent recruiting trials for Natrunix in RA and axSpA indicate progress toward key data readouts, which could validate the platform and drive value. However, XBiotech remains a high-risk investment given its clinical-stage status and the competitive landscape for inflammatory disease therapies.

Upcoming Catalysts (preview)

• Q4 2027Phase 2 data readout for Natrunix in Rheumatoid Arthritis (NCT06590090)40% success
• Q2 2027Phase 2 data readout for Natrunix in Axial Spondyloarthritis (NCT06526377)35% success
• TBDPotential partnership or licensing deal for True Human™ platform20% success